Pharmacotherapy for lumbago
<div class="column"><p><span>Nonspecific low back pain (NLBP) is one of the most common rheumatic disorders; it is responsible for the greatest number of patients seeking medical advice. Unfortunately, there is neither a generally acknowledged viewpoint on the nature of t...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2014-05-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | http://mrj.ima-press.net/index.php/mrj/article/view/539 |
| Summary: | <div class="column"><p><span>Nonspecific low back pain (NLBP) is one of the most common rheumatic disorders; it is responsible for the greatest number of patients seeking medical advice. Unfortunately, there is neither a generally acknowledged viewpoint on the nature of this pathology nor a unified conception of its treatment in Russia. The unreasonably wide use of expensive instrumental diagnostic methods and treatment options that have unconfirmed and disputable efficiency is a serious problem in managing NLBP patients. </span></p><p><span>Nonsteroidal anti-inflammatory drugs (NSAIDs) have been and remain basic medications used to treat NLBP. Their therapeutic potential has been proved in a large number of well-designed clinical trials and it is beyond any doubt. At the same time, there are new NLBP pharma- cotherapies, such as epidural injection of tumor necrosis factor-α inhibitors, the use of nerve growth factor inhibitors and nociceptive system dysfunction-affecting drugs. </span></p><p><span>This paper considers the main groups of drugs (NSAIDs, paracetamol, opioids, myorelaxants, antidepressants and anticonvulsants, glucocor- ticoids, local anesthetics, and genetically engineered biological agents) that have found application or tested in NLBP and gives general data on their efficacy and tolerability. </span></p></div> |
|---|---|
| ISSN: | 1996-7012 2310-158X |